Accueil   Diary - News   All news Focus on: Theranexus

Focus on: Theranexus

Theranexus is a biotechnology company spun off from CEA and member of Lyonbiopole. She has just completed a fundraising of € 3.6m thanks to Auriga Partners, CEA Investissement (Boot Technological Investment Fund ) of Emergence Innovation 1 Managed by Sofimac Partners and Rhône-Alpes Creation. This fundraising will help the launch of the clinical program leading society, THN102 , for the treatment of narcolepsy, debilitating orphan disease touching chronically sleep and wakefulness.

 

 17112014 - Theranexus levée de fonds - FR

 

ABOUT THERANEXUS

Founded in 2013, Theranexus is a biotechnology company designing and developing combinations of drugs to improve the efficiency and safety of some treatments for neurological and psychiatric referred. It was supported by the Directorate of the living and the technology transversal program for health sciences at the CEA and CEA Investment company that was involved early in the project before the company was created. CEA Investissement has worked with leaders and Board of Directors for the development of the strategy and the choice of the first indications as well as the outcome of this fundraiser.

 

For further information on their website

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree